This week, our President and Managing Director, Jennifer Che, attended the Asia Summit for Global Health at the Hong Kong Convention and Exhibition Centre (HKCEC). She was truly impressed by the variety of health-related start-ups, projects, prototypes, and collaborations showcased at the event. The advancements in therapeutics, traditional Chinese medicine, diagnostics, surgical equipment, robotics, and AI solutions highlighted the dynamic biotech landscape of Hong Kong today—a stark contrast to when she first arrived.

Jennifer particularly noted the remarkable initiatives emerging from the InnoHK Centres, which stem from collaborations between local and international universities. Reflecting on the event, she echoed Nancy Ip's sentiment at the HKUST reception: “We can’t do it alone. The most important thing is to collaborate.” This collaborative spirit is vital for driving innovation and improving global health outcomes.

我们的过去活动

Recommended Insights

Everything you need to know about Patent Term Adjustment (PTA) in China

2024年5月7日
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

2021年5月28日
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

Obviousness: can features from different categories of products be combined to invalidate a design patent?

2025年9月18日
Introduction “I have a tank, I have a gun—boom! Tank gun?” Each year the CNIPA releases a list of Top Ten Patent Re-examination and Invalidation Cases. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Over the next several months we will be highlighting many […]
Top crossarrow-right